Helsinki

• A study on the immune response, safety and the occurrence of RSV-associated respiratory tract illness after administration of RSV OA vaccine … Ended
  2023-509455-13-00 11 2024-08-05 Respiratory Syncytial Virus Infections
• EFFICACY AND SAFETY OF GSK4527226 [AL101] IN PATIENTS WITH EARLY ALZHEIMER’S DISEASE Ended
  2023-505083-11-01 4 2024-05-07 Alzheimer's Disease
• A Study of the Efficacy, Safety, and Tolerability of KAN-101 in Participants With Celiac Disease Ended
  2023-507240-37-00 4 2024-04-30 celiac disease
• Safety and Immunogenicity of V116 in Children and Adolescents With Increased Risk for Pneumococcal Disease Ended
  2023-506236-32-00 5 2024-03-25 Pneumococcal disease
• Study on immunogenicity and safety of a meningococcal ACYW conjugate vaccine in healthy infants and toddlers Ended
  2023-508177-85-00 5 2024-03-12 Healthy volunteers (Meningococcal infection)
• A Phase 1b, Open-Label, Multiple Ascending Dose, Multicenter Study of VRG50635 in Participants With Sporadic and Familial Amyotrophic Latera … Ended
  2023-506509-21-00 3 2024-03-08 Amyotrophic Lateral Sclerosis
• A study to test whether BI 456906 helps people living with overweight or obesity who do not have diabetes to lose weight Ended
  2022-502529-17-00 5 2024-01-18 Obesity
• A study to test whether BI 456906 helps people living with overweight or obesity who also have diabetes to lose weight Ended
  2022-502531-18-00 5 2024-01-18 Obesity
• A study to evaluate the safety, tolerability and distribution of TB0010 in head and neck squamous cell carcinoma Ended
  2024-517779-19-00 1 2024-01-05 EGFR-Positive Head and Neck Squamous Cell Carcinoma
• A double-blind, randomized, placebo-controlled study to evaluate the efficacy, safety, and tolerability of intravenous ganaxolone added to s … Ended
  2022-502540-12-00 5 2023-11-09 Refractory Status Epilepticus (RSE)
• A Phase 2 Safety and Immunogenicity Study of a Monovalent Pneumococcal Conjugate Candidate in Healthy Toddlers Ended
  2023-505154-18-00 4 2023-11-02 Pneumococcal Infections
• A Phase 2 Study Evaluating INCB099280 in Participants With Advanced Cutaneous Squamous Cell Carcinoma Ended
  2022-502476-23-00 4 2023-10-25 Treatment of immunotherapy-naive patients with previously untreated or
• A clinical study of MK-0616 for people with high amounts of low-density lipoprotein cholesterol Ended
  2022-502782-14-00 5 2023-09-28 Heterozygous Familial Hypercholesterolemia (HeFH)
• A Clinical Study that will measure how well SEP-363856 works and how safe it is in adults with Generalized Anxiety Disorder Ended
  2022-502077-42-00 10 2023-09-14 generalised anxiety disorder
• Phase 2/3 Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer Ended
  2022-502196-31-00 10 2023-08-21 Advanced or Recurrent Endometrial Cancer
• UNITAS Ended
  2022-502483-21-00 4 2023-07-28 Insomnia disorder
• A study to characterize the pharmacokinetic profile of norucholic acid (NCA) in patients with primary sclerosing cholangitis (PSC) Ended
  2023-507027-37-00 3 2023-07-20 Primary Sclerosing Cholangitis (PSC)
• Long-term Safety and Efficacy of Efavaleukin Alfa in Subjects With Moderately to Severely Active Ulcerative Colitis Ended
  2023-506046-24-00 4 2023-07-03 Ulcerative Colitis (UC)
• A Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab (AMG 451) Monotherapy in Moderate-to-severe AD (ROCKET-Horizon) Ended
  2022-501538-44-00 5 2023-04-25 Atopic Dermatitis
• Long-term Efficacy and Safety of Tozorakimab in Participants with Chronic Obstructive Pulmonary Disease with a History of Exacerbations. Ended
  2022-501063-41-00 5 2023-04-20 Chronic Obstructive Pulmonary Disease (COPD)
• An efficacy and safety study of HRO350 in patients with mild-to-moderate psoriasis (the ‘HeROPA’ study) Ended
  2022-501850-12-00 4 2023-03-15 Psoriasis
• C4951004 - BHV3000-406: A Phase 4, Randomized, Double-blind Placebo Controlled, Efficacy and Tolerability Trial of Rimegepant for the Acute … Ended
  2024-513269-37-00 6 2023-03-14 Migraine attacks with or without aura
• C4951012 - BHV3000-407: A Phase 4, Randomized, Double-blind, Placebo controlled Study to Evaluate the Efficacy and Tolerability of Rimegepan … Ended
  2024-513270-21-00 6 2023-03-14 migraine headaches with or without aura
• A study to test asundexian for preventing a stroke caused by a clot in participants after an acute ischemic stroke or after a high-risk tran … Ended
  2023-503793-20-00 5 2023-01-18 Prevention of ischemic stroke in patients post acute non-cardioembolic

Showing 313–336 of 374 trials